Amgen Finalizes Agreement Resolving Previously Announced Federal Investigations

       Amgen Finalizes Agreement Resolving Previously Announced Federal
                                Investigations

$762 Million Agreement Covered by 3rd Quarter 2011 Charge

PR Newswire

THOUSAND OAKS, Calif., Dec. 19, 2012

THOUSAND OAKS, Calif., Dec. 19, 2012 /PRNewswire/ --Amgen (NASDAQ:AMGN) today
announced it has finalized a settlement agreement with the U.S. government, 49
states and the District of Columbia related to previously disclosed
investigations.

Amgen will pay approximately $612 million to resolve its civil liability
related to certain promotional practices related to the drugs Aranesp^®
(darbepoetin alfa), EPOGEN^® (epoetin alfa), NEUPOGEN^® (Filgrastim),
Neulasta^® (pegfilgrastim), Enbrel^® (etanercept) and Sensipar^® (cinacalcet)
as alleged in the unsealed qui tam complaints and $150 million to resolve its
criminal liability relating to the marketing of Aranesp. The Company also
entered into a Corporate Integrity Agreement with the Office of Inspector
General of the U.S. Department of Health and Human Services.

"I am pleased a settlement was reached to conclude this matter. With the
emphasis and investment we have made in compliance, I am confident about
Amgen's continued adherence to the provisions in this agreement," said Robert
A. Bradway, chief executive officer at Amgen. "Amgen remains dedicated to
advancing science to dramatically improve people's lives. We are committed to
meeting the expectations of the government and the healthcare community as we
fulfill our mission in serving the needs of patients."

As part of the agreement, Amgen has pleaded guilty to a single misdemeanor
count of misbranding Aranesp by promoting it in a way that was different from
the dosages in the label. The plea was entered yesterday in the U.S. District
Court for the Eastern District of New York and was accepted today by the same
Court.

"The government raised important concerns in the criminal prosecution. Amgen
acknowledges that mistakes were made, and we did not live up to our
standards," said Cynthia M. Patton, senior vice president and chief compliance
officer at Amgen. "This Corporate Integrity Agreement is aligned with the
significant changes and enhancements we have made to our compliance program
and demonstrates our commitment to fostering a culture of compliance at
Amgen."

About Amgen
Amgen discovers, develops, manufactures and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first
companies to realize the new science's promise by bringing safe, effective
medicines from lab to manufacturing plant to patient. Amgen therapeutics have
changed the practice of medicine, helping millions of people around the world
in the fight against cancer, kidney disease, rheumatoid arthritis, bone
disease and other serious illnesses. With a deep and broad pipeline of
potential new medicines, Amgen remains committed to advancing science to
dramatically improve people's lives. To learn more about our pioneering
science and vital medicines, visit www.amgen.com. Follow us on
www.twitter.com/amgen.

Forward-Looking Statements
This news release contains forward-looking statements that involve significant
risks and uncertainties, including those discussed below and others that can
be found in our Form 10-K for the year ended Dec. 31, 2011, and in our
periodic reports on Form 10-Q and Form 8-K. Amgen is providing this
information as of the date of this news release and does not undertake any
obligation to update any forward-looking statements contained in this document
as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ
materially from those we project. The Company's results may be affected by
our ability to successfully market both new and existing products domestically
and internationally, clinical and regulatory developments (domestic or
foreign) involving current and future products, sales growth of recently
launched products, competition from other products (domestic or foreign) and
difficulties or delays in manufacturing our products. In addition, sales of
our products are affected by reimbursement policies imposed by third-party
payers, including governments, private insurance plans and managed care
providers and may be affected by regulatory, clinical and guideline
developments and domestic and international trends toward managed care and
health care cost containment as well as U.S. legislation affecting
pharmaceutical pricing and reimbursement. Government and others' regulations
and reimbursement policies may affect the development, usage and pricing of
our products. Furthermore, our research, testing, pricing, marketing and
other operations are subject to extensive regulation by domestic and foreign
government regulatory authorities. We, or others, could identify safety, side
effects or manufacturing problems with our products after they are on the
market. Our business may be impacted by government investigations, litigation
and product liability claims. Further, while we routinely obtain patents for
our products and technology, the protection offered by our patents and patent
applications may be challenged, invalidated or circumvented by our
competitors. We depend on third parties for a significant portion of our
manufacturing capacity for the supply of certain of our current and future
products and limits on supply may constrain sales of certain of our current
products and product candidate development. In addition, we compete with
other companies with respect to some of our marketed products as well as for
the discovery and development of new products. Discovery or identification of
new product candidates cannot be guaranteed and movement from concept to
product is uncertain; consequently, there can be no guarantee that any
particular product candidate will be successful and become a commercial
product. Further, some raw materials, medical devices and component parts for
our products are supplied by sole third-party suppliers. Our business
performance could affect or limit the ability of our Board of Directors to
declare a dividend or our ability to pay a dividend or repurchase our common
stock.

CONTACT: Amgen, Thousand Oaks
Ashleigh Koss, 805-313-6151 (media)
Arvind Sood, 805-447-1060 (investors)

(Logo: http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)

SOURCE Amgen

Website: http://www.amgen.com
 
Press spacebar to pause and continue. Press esc to stop.